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Dominant negative c-Src inhibits angiotensin II induced activa-
tion of NHE3 in OKP cells.
Background. Angiotensin II is a potent stimulator of the
proximal tubule apical membrane Na/H antiporter, encoded by
NHE3. The nonreceptor tyrosine kinase, c-Src, plays a key role in
regulation of NHE3 by acidosis in the proximal tubule, and in
signaling effects of angiotensin II in vascular smooth muscle.
Methods. The present studies examined the role of c-Src in
mediating angiotensin II-induced NHE3 activation in cultured
OKP cells. c-Src was inhibited with herbimycin A, a tyrosine
kinase inhibitor, and expression of a dominant negative c-Src,
c-SrcK295M.
Results. Herbimycin A blocked angiotensin II induced increases
in Na/H antiporter activity. In two clonal cell lines expressing
vector alone, angiotensin II increased Na/H antiporter activity,
while in three clones expressing c-SrcK295M, angiotensin II had no
effect. Cyclic AMP and protein kinase A have been proposed to
be key mediators in regulation of NHE3 by angiotensin II. 1024 M
8-bromo cAMP induced a 40 to 50% inhibition of Na/H antiporter
activity in cells expressing c-SrcK295M, similar to that seen in
wild-type OKP cells. In addition, cells expressing c-SrcK295M
responded normally to 1027 M dexamethasone with a 50 to 80%
increase in Na/H antiporter activity.
Conclusions. These studies demonstrate that c-Src is required
for angiotensin II-induced increases in NHE3 activity. Thus, c-Src
plays a key role in antiporter activation by acidosis and angioten-
sin II.
Angiotensin II stimulates the proximal tubule apical
membrane Na/H antiporter [1], which leads to increased
rates of NaCl and NaHCO3 absorption [2–6]. However, the
signaling pathways responsible remain unresolved. Much
attention has focused on the role of adenylyl cyclase, with
angiotensin II inhibiting adenylyl cyclase, and decreased
cAMP levels and protein kinase A activity resulting in
stimulation of the Na/H antiporter [7, 8]. However, there is
also evidence for significant contributions from other sig-
naling pathways, including protein kinase C, cell Ca21
regulated pathways, and icosanoids [9]. Tyrosine kinase
pathways, and specifically c-Src, have been demonstrated to
play a key role in angiotensin II-induced proliferation in
vascular smooth muscle cells [10].
The Na/H antiporter isoform, NHE3, has been localized
to the proximal tubular apical membrane, and encodes a
significant fraction of apical membrane Na/H antiporter
activity [11, 12]. The OKP cell is an opossum kidney cell
line which expresses NHE3 [13]. Similar to the proximal
tubule apical membrane Na/H antiporter, the OKP cell (or
the parent OK cell) antiporter is stimulated by endothelin,
acidosis, and glucocorticoids, and is inhibited by PTH and
exogenous cAMP analogs [13–16]. We previously found
that angiotensin II stimulated NHE3 activity in OKP cells,
in spite of the fact that it did not regulate cAMP production
in these cells [17]. Thus, OKP cells provide an ideal cell to
study cAMP-independent mechanisms of NHE3 regulation
by angiotensin II. In the present study, we demonstrate that
functional c-Src, a nonreceptor tyrosine kinase, is required
for regulation of NHE3 by angiotensin II.
METHODS
Materials and supplies
All chemicals were obtained from Sigma Chemical Co.
(St. Louis, MO, USA) unless otherwise noted as follows:
penicillin and streptomycin from Whittaker M. A. Bioprod-
ucts (Walkersville, MD, USA); acetoxymethyl derivative of
2979-bis(2-carboxyethyl)-5-(and-6)-carboxyfluorescein
(BCECF) from Molecular Probes, Inc. (Eugene, OR,
USA); culture media from Gibco BRL (Grand Island, NY,
USA); and Tfx-50 from Promega (Madison, WI, USA).
Cell culture
OKP cells [18] were passaged in high glucose (450 mg/dl)
Dulbecco’s modified Eagle’s media (DMEM) supple-
mented with 10% fetal bovine serum, penicillin (100 U/ml),
and streptomycin (100 mg/ml). When confluent, cells were
rendered quiescent for 48 hours prior to study by removal
of serum and were placed in a 1:1 mixture of low glucose
(100 mg/dl) DMEM and Ham’s F12.
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Dominant negative c-SrcK295M was created by site di-
rected mutagenesis as described by the manufacturer
(Sculptory in vitro mutagenesis system; Amersham Life
Science), cloned into a CMV promoter driven pCI-neo
expression vector, and transfected into OKP cells using
Tfx-50, as described by the manufacturer. Neomycin resis-
tant cells were selected by growth in 400 mg/ml G-418 and
maintained in 200 mg/ml G-418. Clonal cell lines were
isolated by limiting dilution, and screened by Northern blot
for maximal expression of c-SrcK295M. For experimentation,
G-418 was removed two days prior to study. Control cells
were transfected with vector alone, cloned, and treated
similarly to experimental cells.
To study the effects of angiotensin II, cells were incu-
bated in 10210 M angiotensin II or vehicle (0.001 N HCl) for
45 minutes. To study the effects of glucocorticoid hormone,
cells were incubated in 0.1 mM dexamethasone or vehicle
(ethanol) for 24 hours. To study the effects of cAMP, cells
were incubated in 1024 M 8-bromo cAMP or vehicle
(ethanol) for 45 minutes.
Measurement of intracellular pH and Na/H antiporter
activity
Continuous measurement of cytoplasmic pH (pHi) was
accomplished using the intracellularly trapped pH-sensitive
dye, BCECF, as previously described [19]. Cells were
loaded with 10 mM acetoxymethyl ester of BCECF for 35
minutes at 37°C, and pHi estimated from the ratio of
fluorescence with excitation at wavelengths of 500 and 450
nm, with 530 nm emission in a computer-controlled spec-
trofluorimeter (8000C; SLM Instruments, Inc., Urbana, IL,
USA). The BCECF excitation fluorescence ratio was cali-
brated intracellularly using K/nigericin as described [20].
Calibration was the same in all clonal cell lines.
Na/H antiporter activity was assayed as the initial rate of
Na1-dependent pHi increase following an acid load in the
absence of CO2/HCO3, as previously described [19]. Cells
were acidified with 13 mM nigericin in Na1-free solution.
The initial rate of pHi increase (dpHi/dt) upon Na
1
addition was calculated by drawing a line tangent to the
initial deflection. Angiotensin II had no effect on buffer
capacity [17]. Results are therefore reported as dpHi/dt.
RESULTS
To examine whether tyrosine kinases play a key role in
angiotensin II induced activation of the OKP cell Na/H
antiporter, we examined the effect of herbimycin A. Her-
bimycin A inhibits many tyrosine kinases, but is especially
potent against c-Src family members [21]. Herbimycin A, 1
mM, was added 24 hours prior to addition of angiotensin II.
Figure 1 shows the results. 10210 M angiotensin II caused a
20% increase in Na/H antiporter activity in cells treated
with vehicle (DMSO) (P , 0.05). While this effect is small,
it is consistent, and similar to that which we previously
reported in OKP cells [17]. Herbimycin A had no effect on
basal Na/H antiporter activity, but completely inhibited
activation by angiotensin II (2% increase, NS).
c-Src is a nonreceptor tyrosine kinase that is expressed in
the renal proximal tubule [22]. We have demonstrated that
c-Src plays a key role in Na/H antiporter activation by acid
[23, 24]. In addition, c-Src has been proposed to play a key
role in angiotensin II-induced growth in vascular smooth
muscle cells [10, 25]. There are no tyrosine kinase inhibitors
that are specific for c-Src. To examine the role of c-Src in
angiotensin II mediated stimulation of the OKP cell Na/H
antiporter, we used a dominant negative approach. Domi-
nant negative c-Src was generated by mutating lysine 295 to
methionine, yielding a kinase-inactive c-Src. Courtneidge
and coworkers demonstrated that expression of c-SrcK295M
inhibits the proliferative response that occurs in response
to PDGF, EGF, and CSF-1 [26, 27]. OKP cells were stably
transfected with c-SrcK295M or with vector alone.
Figure 2 shows the effect of 10210 M angiotensin II on
Na/H antiporter activity in OKP cells transfected with
vector alone or c-SrcK295M. Angiotensin II consistently
induced a 15 to 20% increase in Na/H antiporter activity in
vector expressing cells (P , 0.02). However, in three clones
expressing c-SrcK295M, angiotensin II failed to increase
Na/H antiporter activity (c-SrcK295M-1 cells, 24%, NS;
c-SrcK295M-2 cells, 16%, NS; and c-SrcK295M-8 cells, 12%,
NS).
To address whether expression of dominant negative
c-SrcK295M nonspecifically inhibited activation of NHE3 by
Fig. 1. Herbimycin A blocks angiotensin II-induced activation of the
Na/H antiporter. Cells were preincubated with 1 mM herbimycin A or
vehicle for 24 hours, and then treated with 10210 M angiotensin II for 45
minutes. Na/H antiporter activity is plotted as the initial rate of change in
cell pH upon Na1 addition. *P , 0.05 versus control. Abbreviations are:
Con, control; Ang II, angiotensin II.
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any mechanism, we examined glucocorticoid-induced stim-
ulation of Na/H antiporter activity. We previously showed
that antiporter activation by glucocorticoids was not inhib-
ited by herbimycin A [23]. Figure 3 shows that 1027 M
dexamethasone 3 24 hours caused a consistent increase in
Na/H antiporter activity in c-SrcK295M cells (c-SrcK295M-1
cells, 152%, P , 0.001; c-SrcK295M-2 cells, 156%, P ,
0.001; and c-SrcK295M-8 cells, 181%, P , 0.001). This
magnitude of response is similar to that which we found in
wild-type OKP cells (152% increase, P , 0.05, N 5 5), and
is similar to that which we have previously observed [15].
One possible explanation for the above results is that
c-Src is downstream of other signaling pathways. Given the
evidence for a role of cAMP in angiotensin II signaling [2,
7, 8], we investigated whether cAMP-induced regulation of
NHE3 was inhibited by c-SrcK295M. As shown in Figure 4,
1024 M 8-bromo cAMP inhibited Na/H antiporter activity in
each of the three clones expressing c-SrcK295M (c-
SrcK295M-1 cells, 246%, P , 0.001; c-SrcK295M-2 cells,
246%, P , 0.001; and c-SrcK295M-8 cells, 242%, P ,
0.001). This degree of inhibition is similar to that which we
have observed previously with 8-bromo cAMP in OKP cells
[19]. Thus, inhibition of the antiporter by cAMP was intact
in these cells.
DISCUSSION
Angiotensin II is a potent antinatriuretic hormone. A
significant component of this effect is mediated by stimu-
lation of proximal tubular NaHCO3 and NaCl transport
[3–6]. Increases in these fluxes are mediated by parallel
activation of the apical membrane Na/H antiporter and the
basolateral membrane Na/HCO3/CO3 cotransporter [1,
28]. The present studies examined the mechanism by which
angiotensin II increases the activity of the apical membrane
antiporter encoded by NHE3 [11, 12]. Studies were per-
formed in OKP cells, which express NHE3, and in which
angiotensin II has been demonstrated to increase NHE3
activity [17].
Previous studies have suggested an important role for
adenylyl cyclase inhibition in mediating angiotensin-in-
duced Na/H antiporter stimulation in the proximal tubule.
Angiotensin II has been demonstrated to inhibit cAMP
generation in these cells, and protein kinase A is known to
inhibit the Na/H antiporter [2, 7, 8]. Also, addition of
exogenous cAMP analogs prevents angiotensin II induced
increases in transport [7]. Nevertheless, it remains possible
that other signaling pathways may also contribute to regu-
lation by angiotensin II.
In OKP cells, angiotensin II was found to stimulate the
activity of an ethylisopropyl amiloride-resistant Na/H anti-
porter, likely NHE3, by approximately 15 to 20% [17]. This
effect was mediated by the AT1 receptor, similar to regu-
lation in the intact proximal tubule [17]. In spite of this,
angiotensin II was found to have no effect on cAMP
production in these cells [17]. This finding does not argue
against regulation of cAMP production in the intact prox-
imal tubule, but demonstrates that binding of angiotensin II
to the AT1 receptor can activate NHE3 in the absence of
adenylyl cyclase regulation. These cells are thus ideal for
studying the mechanism of cAMP-independent regulation.
c-Src is a nonreceptor tyrosine kinase that is expressed in
the renal proximal tubule [22]. In vascular smooth muscle
cells, angiotensin II activates c-Src [25]. Electroporation of
anti-c-Src antibodies into rat aortic smooth muscle cells
inhibited angiotensin II-induced cell proliferation [10]. To
address the role of c-Src in angiotensin II-induced NHE3
activation, we used two approaches. First we demonstrated
that herbimycin A inhibited the response. Herbimycin A is
a tyrosine kinase inhibitor of broad specificity that is known
to potently inhibit c-Src [21]. Because there are no specific
inhibitors of c-Src, we used a dominant negative approach
similar to that of Courtneidge and coworkers [26, 27]. Cells
expressing dominant negative c-SrcK295M did not respond
to angiotensin II while vector expressing cells responded
normally. Expression of c-SrcK295M did not impair the
health of the cells. They appeared normal, grew normally,
and responded in a normal fashion to dexamethasone.
Given the fact that similar inhibition was observed in all
three clones, it is unlikely that this effect is due to nonspe-
cific integration into and disruption of random genes. In
addition, we have shown that the stimulation of NHE3
induced by media acidification is inhibited in the three
clones of c-SrcK295M expressing cells studied here [29].
Much evidence suggests that this effect of media acidifica-
tion is mediated by c-Src: (1) herbimycin A blocks the
effect; (2) overexpression of csk, an endogenous inhibitor
Fig. 2. Dominant negative c-SrcK295M inhibits activation of the Na/H
antiporter by angiotensin II. Cells expressing dominant negative
c-SrcK295M or vector were treated with 10210 M angiotensin II for 45
minutes. Na/H antiporter activity is plotted as the initial rate of change in
cell pH upon Na1 addition. *P , 0.02 versus control. Abbreviations are:
C, control; A, angiotensin II.
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of c-Src, inhibits the effect of acidosis; and (3) acidosis does
not stimulate NHE3 activity in c-src knockout mice [23, 30].
Because of the significant amount of evidence linking
cAMP to angiotensin induced antiporter regulation, we
examined the regulation of the antiporter by cAMP in these
cells. 1024 M 8-bromo cAMP caused antiporter inhibition in
c-SrcK295M cells that was similar to that which has been
observed in wild-type OKP cells. Thus, c-Src does not
function downstream from cAMP or protein kinase A.
The role played by c-Src is not clear. c-Src could directly
phosphorylate NHE3 or an NHE3 associated protein. It is
more likely that c-Src initiates a phosphorylation cascade
resulting in regulation of NHE3. The observation that c-Src
is required for antiporter activation does not preclude an
important role for other signaling pathways. It is possible
that antiporter activation requires multiple signaling path-
ways functioning in series or in parallel. Tyrosine kinases
have now been demonstrated to play a key role in NHE3
Fig. 3. Dominant negative c-SrcK295M does not
inhibit activation of the Na/H antiporter by
dexamethasone. Cells expressing dominant
negative c-SrcK295M were treated with 1027 M
dexamethasone for 24 hours. Na/H antiporter
activity is plotted as the initial rate of change in
cell pH upon Na1 addition. *P , 0.001 versus
control. Abbreviations are: Con, control; Dex,
dexamethasone.
Fig. 4. Dominant negative c-SrcK295M does not
inhibit inhibition of the Na/H antiporter by 8-
bromo cAMP. Cells expressing dominant
negative c-SrcK295M were treated with 1024 M
8-bromo cAMP for 45 minutes. Na/H antiporter
activity is plotted as the initial rate of change in
cell pH upon Na1 addition. *P , 0.001 versus
control. Abbreviations are: Con, control;
cAMP, 8-bromo cAMP.
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regulation by acidosis, endothelin, and angiotensin II [23,
31]. In the case of acidosis and angiotensin II, at least one
of the required tyrosine kinases is c-Src.
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